Literature DB >> 31482495

X-Ray Crystallography in Structure-Function Characterization of Therapeutic Enzymes.

Anastassios C Papageorgiou1.   

Abstract

Enzymes are key biological macromolecules that support life by accelerating the conversion of target molecules to desired products in many biochemical reactions. Enzymes are characterized by high affinity, specificity and great catalytic efficiency. Owing to their unique characteristics, enzymes have attracted significant attention for use in therapeutic settings as a distinct class of drugs different from other types of medicines. Enzyme-based therapies are currently in use for the treatment of a wide range of diseases, including leukemia, metabolic disorders, inflammation and cardiovascular disease. However, several challenges, such as immunogenicity and stability, remain. X-ray crystallography has provided key structural insights into the understanding of the molecular basis of diseases and development of enzyme-based therapies. Here, the role of X-ray crystallography in the development of therapeutic enzymes is examined and several examples are provided.

Entities:  

Keywords:  Chaperones; Enzyme deficiency; Enzyme stability; Enzyme therapy; Structure stabilizers

Mesh:

Substances:

Year:  2019        PMID: 31482495     DOI: 10.1007/978-981-13-7709-9_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  66 in total

1.  Asparaginases: a successful class of drugs against leukemias and lymphomas.

Authors:  Vassilios I Avramis
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

2.  Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease.

Authors:  Boris Brumshtein; Mark R Wormald; Israel Silman; Anthony H Futerman; Joel L Sussman
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-11-23

3.  Monitoring protein aggregation during thermal unfolding in circular dichroism experiments.

Authors:  Sangeeta Benjwal; Shikha Verma; Klaus-Heinrich Röhm; Olga Gursky
Journal:  Protein Sci       Date:  2006-02-01       Impact factor: 6.725

Review 4.  Microbial production of nattokinase: current progress, challenge and prospect.

Authors:  Dongbo Cai; Chengjun Zhu; Shouwen Chen
Journal:  World J Microbiol Biotechnol       Date:  2017-04-04       Impact factor: 3.312

Review 5.  Gaucher disease and its treatment options.

Authors:  Lunawati L Bennett; Devipriya Mohan
Journal:  Ann Pharmacother       Date:  2013-09       Impact factor: 3.154

6.  Crystal structure of phenylalanine ammonia lyase: multiple helix dipoles implicated in catalysis.

Authors:  Joseph C Calabrese; Douglas B Jordan; Amechand Boodhoo; Sima Sariaslani; Todd Vannelli
Journal:  Biochemistry       Date:  2004-09-14       Impact factor: 3.162

7.  Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display.

Authors:  Kai-Chuan Chen; Chia-Hung Wu; Chuan-Yuan Chang; Wei-Cheng Lu; Qingzong Tseng; Zeljko M Prijovich; Wolfgang Schechinger; Yen-Chywan Liaw; Yu-Lin Leu; Steve R Roffler
Journal:  Chem Biol       Date:  2008-12-22

8.  Insights into mucopolysaccharidosis I from the structure and action of α-L-iduronidase.

Authors:  Haiying Bie; Jiang Yin; Xu He; Allison R Kermode; Ethan D Goddard-Borger; Stephen G Withers; Michael N G James
Journal:  Nat Chem Biol       Date:  2013-09-11       Impact factor: 15.040

9.  A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation.

Authors:  David Aviezer; Einat Brill-Almon; Yoseph Shaaltiel; Sharon Hashmueli; Daniel Bartfeld; Sarah Mizrachi; Yael Liberman; Arnold Freeman; Ari Zimran; Eithan Galun
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

10.  Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.

Authors:  Sean M Bell; Dan J Wendt; Yanhong Zhang; Timothy W Taylor; Shinong Long; Laurie Tsuruda; Bin Zhao; Phillip Laipis; Paul A Fitzpatrick
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.